Retinoblastoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Retinoblastoma – Drugs In Development, 2024 report and make more profitable business decisions.
Retinoblastoma is an eye cancer that begins in the retina. Symptoms include white color in the center circle of the eye (pupil), eye redness, vision problems, a different color in each iris, and eye swelling. The predisposing factors include age and heredity. Treatment includes chemotherapy, radiation therapy, and surgery.
The Retinoblastoma drugs in development market research report provide comprehensive information on the therapeutics under development for Retinoblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinoblastoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Retinoblastoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 13 molecules, with 13 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Retinoblastoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Retinoblastoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Retinoblastoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Ascentage Pharma Group InternationalBeijing zhikangbo Medical Oncology Research Co Ltd
Canget BioTekpharma LLC
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Innovation Pharmaceuticals Inc
Oxular Ltd
PepVax Inc
Qualix DoT sl
Spectocular LLC
Targeted Therapy Technologies LLC
VCN Biosciences SL
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Retinoblastoma reports